EP1685151A4 - Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux - Google Patents

Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Info

Publication number
EP1685151A4
EP1685151A4 EP04800514A EP04800514A EP1685151A4 EP 1685151 A4 EP1685151 A4 EP 1685151A4 EP 04800514 A EP04800514 A EP 04800514A EP 04800514 A EP04800514 A EP 04800514A EP 1685151 A4 EP1685151 A4 EP 1685151A4
Authority
EP
European Patent Office
Prior art keywords
peptides
treatment
methods
brain disorders
neuronal regeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04800514A
Other languages
German (de)
English (en)
Other versions
EP1685151A2 (fr
Inventor
Frank Sieg
Thorsten Gorba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuren Pharmaceuticals Ltd
Original Assignee
NEUREN PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUREN PHARMACEUTICALS Ltd filed Critical NEUREN PHARMACEUTICALS Ltd
Publication of EP1685151A2 publication Critical patent/EP1685151A2/fr
Publication of EP1685151A4 publication Critical patent/EP1685151A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
EP04800514A 2003-10-31 2004-11-01 Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux Withdrawn EP1685151A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51601803P 2003-10-31 2003-10-31
US58504104P 2004-07-02 2004-07-02
US61627104P 2004-10-05 2004-10-05
PCT/US2004/036203 WO2005042561A2 (fr) 2003-10-31 2004-11-01 Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Publications (2)

Publication Number Publication Date
EP1685151A2 EP1685151A2 (fr) 2006-08-02
EP1685151A4 true EP1685151A4 (fr) 2009-04-22

Family

ID=34557374

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04800514A Withdrawn EP1685151A4 (fr) 2003-10-31 2004-11-01 Regeneration neuronale de peptides et methodes d'utilisation dans le traitement des troubles cerebraux

Country Status (3)

Country Link
EP (1) EP1685151A4 (fr)
JP (1) JP5026083B2 (fr)
WO (1) WO2005042561A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121926A2 (fr) * 2005-05-06 2006-11-16 Neuren Pharmaceuticals Limited Peptides de regeneration neurale (nrp) et procedes pour les utiliser
WO2007011595A2 (fr) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Peptides de regeneration neurale et antioxydants protegeant les neurones de la degenerescence
JP2009513689A (ja) * 2005-10-31 2009-04-02 ラボラトワール セローノ ソシエテ アノニム 神経学的疾患の治療、及び／又は予防のためのｓｄｆ−１の使用
ES2433568T3 (es) * 2007-10-17 2013-12-11 Curonz Holdings Company Limited Análogos sintéticos de péptidos de regeneración neuronal
WO2013112002A1 (fr) * 2012-01-27 2013-08-01 의료법인 성광의료재단 Biomarqueur destiné à réduire ou soulager des symptômes de lésion cérébrale
AU2013293645B2 (en) * 2012-07-27 2018-04-12 Curonz Holdings Company Limited Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
JP2017501967A (ja) 2013-10-11 2017-01-19 タリックス ファーマシューティカルズ リミテッド 新規なペプチド組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018754A2 (fr) * 2001-08-24 2003-03-06 Neuronz Limited Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995006662A1 (fr) * 1993-09-01 1995-03-09 Start Technology Partnership Facteur regulateur de neurones servant a promouvoir la survie des neurones

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018754A2 (fr) * 2001-08-24 2003-03-06 Neuronz Limited Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales

Also Published As

Publication number Publication date
WO2005042561A2 (fr) 2005-05-12
WO2005042561A3 (fr) 2006-10-12
JP5026083B2 (ja) 2012-09-12
EP1685151A2 (fr) 2006-08-02
JP2007511210A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
MA29084B1 (fr) Derives d'indenyle et leur utilisation dans le traitement de troubles neurologiques
FR13C0060I2 (fr) Omega-carboxyaryldiphenyluree fluoro-subtituee pour le traitement et la prevention de maladies et d'etats pathologiques
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
FR2869541B1 (fr) Utilisation d'une composition comprenant du d-mannoheptulose et/ou du perseitol dans le traitement et la prevention des maladies liees a une modification de l'immunite innee
EP1850880A4 (fr) Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
EP1465854A4 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
EP2173740A4 (fr) Inhibiteurs de l'hème-oxygénase et leur utilisation dans le traitement du cancer et de maladies du système nerveux central
IL174918A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
IL174185A0 (en) Methods and reagents for the treatment of immunoinflammatory disorders
EP1569636A4 (fr) Utilisation d'equol dans le traitement de maladies d'origine androgenique
EP1781303A4 (fr) Procedes et reactifs pour le traitement de troubles metaboliques
FR15C0030I2 (fr) Composes d'acide benzoique 1,2,4-oxadiazole et utilisation de ceux-ci dans la suppression non-sens et le traitement de maladies
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
EP1366012A4 (fr) Acides 2-aryloxy-2-arylalcano ques utilis s pour le traitement du diab tes et des troubles lipidiques
EP1495130A4 (fr) Utilisation de cibles biomoleculaires dans le traitement et la visualisation de tumeurs cerebrales
ATE369133T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
EP1680009A4 (fr) Compositions et procedes pour le diagnostic et de traitement de troubles mentaux
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
AU2003284968A8 (en) Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
DE60223715D1 (de) Glyt1 transporter inhibitoren und deren anwendung in der behandlung von neurologischen und neuropsychiatischen krankheiten
EP1644039A4 (fr) Compositions et procedes pour le traitement des troubles lies a la coagulation
DE69603456D1 (de) Vorrichtung zur kontrolle von biologischen/medizinischen flüssigkeitsströmen zum und vom patienten
ES2414872T8 (es) Terapia combinada para la prevención o tratamiento de la enfermedad de Alzheimer y kit correspondiente
MA27381A1 (fr) Association synergique d'un ligand de alpha-2-delta et d'un inhibiteur de pdev pour une utilisation dans le traitement de la douleur
NO20033443D0 (no) Anvendelse av CD-2-bindende midler ved behandling eller forebygging av hudlidelser

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060526

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/00 20060101ALI20061125BHEP

Ipc: A01N 37/18 20060101ALI20061125BHEP

Ipc: A01N 61/00 20060101AFI20061125BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEUREN PHARMACEUTICALS LIMITED

A4 Supplementary search report drawn up and despatched

Effective date: 20090319

17Q First examination report despatched

Effective date: 20100121

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20121030